From dorzolamide 2%/timolol 0.5% to brinzolamide 1%/timolol 0.5% fixed combination: a 6-month, multicenter, open-label tolerability switch study

Bibliography

• Risk factors for progression of visual field abnormalities in normal tension glaucoma. Collaborative normal tension glaucoma study group. Am J Ophthalmol 2001;131:699-708
   PubMed Web of Science ®Google Scholar
• Leske MC, Heijl A, Hyman L, Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
   PubMed Web of Science ®Google Scholar
• The ocular hypertension treatment study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of POAG. Arch Ophthalmol 2002;120:701-3
   PubMedGoogle Scholar
• European glaucoma prevention study. Development of primary open angle glaucoma in individuals with ocular hypertension. Ophthalmology 2007;114:10-19
   PubMedGoogle Scholar
• AGIS investigators. The advanced glaucoma intervention study (AGIS):14. Baseline risk factors for sustained loss of visual field and visual acuity in patients with advanced glaucoma. Am J Ophtalmol 2002;134:499-512
   PubMed Web of Science ®Google Scholar
• EGS. Terminology and guidelines for glaucoma. Dogma ed. 3rd edition. Savona, Italy; 2008. p. 12-13
   Google Scholar
• Framptom JE, Perry CM. Topical dorzolamide 2%/timolol 0.5% ophthalmic solution. A review of its use in the treatment of glaucoma and ocular hypertension. drugs aging 2006;23:977-95
   PubMedGoogle Scholar
• Clineschmidt CM, Williams RD, Snyder E, A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol combination study group. Ophthalmology 1998;105:1952-9
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol study group. Ophthalmology 1998;105:1945-51
   PubMed Web of Science ®Google Scholar
• Hutzelmann J, Owens S, Shedden A, Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International clinical equivalence study group. Br J Ophthalmol 1998;82:1249-53
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Dorzolamide-timolol study group. Ophthalmology 1998;105:1936-44
   PubMed Web of Science ®Google Scholar
• Ormrod D, McClellan K. Topical dorzolamide 2%/timolol 0.5%: a review of its use in the treatment of open-angle in glaucoma. Drugs Aging 2000;17:477-96
   PubMed Web of Science ®Google Scholar
• Jampel HD, Schwartz GF, Robin AL, Abrams DA. Patient preferences for eye drop characteristics. A willingness to pay analysis. Arch Ophthalmol 2003;121:540-6
   PubMed Web of Science ®Google Scholar
• Hollo G, Bozkurt B, Irkec M. Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension. Expert Opin Pharmacot 1009;10:2015-24
   Google Scholar
• Manni G, Denis P, Chew P, The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
   PubMed Web of Science ®Google Scholar
• Vold SD, Evans RM, Stewart RH, ; the Brinzolamide/Timolol Comfort Study Group. A one-week comfort study of BID-dosed brinzolamide 1%/timolol 0.5% ophthalmic suspension fixed combination compared to BID-dosed dorzolamide 2%/timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther 2008;24:601-5
   PubMed Web of Science ®Google Scholar
• Mundorf TK, rauchman SH, Williams RD, ; Notivol R brinzolamide/Timolol Preference Study Group. A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clinical Ophthalmol 2008;2:623-8
   PubMedGoogle Scholar
• Nichols KK, Nichols JJ, Zadnik K. Frequency of dry eye diagnostic test procedures used in various modes of ophthalmic practice. Cornea 2000;19:477-82
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Tseng SC, Sanabria O, Evaluation of subjective assessment and objective diagnostic tests for diagnosing tear-film disorders known to cause ocular irritation. Cornea 1998;17:38-56
   PubMed Web of Science ®Google Scholar
• Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 2003;22:640-9
   PubMed Web of Science ®Google Scholar
• Lee BL, Gutierrez P, Gordon M, The glaucoma symptom scale- a brief index of glaucoma-specific symptoms. Arch Ophthalmol 1998;116:861-6
   PubMed Web of Science ®Google Scholar
• Schiffman RM, Christianson MD, Jacobsen G, Reliability and validity of the ocular surface disease index. Arch Ophthalmol 2000;118:615-21
   PubMed Web of Science ®Google Scholar
• Rossi GCM, Tinelli C, Pasinetti GM, Dry eye syndrome-related quality of life in glaucoma patients. Eur J Ophthalmol 2009;4:572-9
   Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure – lowering medications. Cornea 2010;29:618-21
   PubMed Web of Science ®Google Scholar
• Report of the International Dry Eye WorkShop (DEWS). The epidemiology of dry eye disease. Ocular Surf 2007;5:27-41
   Google Scholar
• Begley CG, Chalmers RL, Abetz L, The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003;44:4753-61
   PubMed Web of Science ®Google Scholar
• Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004;23:762-70
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma 2008;17:350-5
   PubMed Web of Science ®Google Scholar
• Tsai JC, McClure CA, Ramos SE, Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ, Stewart WC. For the Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 2003;19:405-15
   PubMed Web of Science ®Google Scholar